Oral Mucosa Articles & Analysis
4 news found
Dr Trilla will apply the knowledge gained from his experience collaborating on over 160 life science partnerships to oversee corporate strategy, business partnerships and lead Intrommune through our business planning process.” The Company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. ...
” Intrommune’s lead product in development, INT301, utilizes the oral mucosal immunotherapy platform (OMIT) to decrease allergic immune response in patients through daily tooth brushing. The product delivers allergenic proteins to areas of the oral cavity to naturally trigger an immune system response towards tolerance of the allergen. ...
Patent No. 9,271,899 entitled, “Methods, Articles and Kits for Allergic Desensitization, via the Oral Mucosa.” The issuing patent including claims to the approach of combining allergenic proteins with toothpaste. These claims provide patent protection for the oral mucosal immunotherapy (OMIT) platform. OMIT enables regular ...
Noroviruses are transmitted primarily through the fecal-oral route, either by consumption of fecally contaminated food or water or by direct person-to-person contact. ...